Generalized Anxiety Disorder Pipeline Outlook, Clinical Trials, FDA Approvals, and Companies 2024 (Updated)

(Albany, United States) As per DelveInsight's assessment, globally, the Generalized Anxiety Disorder Pipeline constitutes 10+ key companies continuously working towards developing 12+ Generalized Anxiety Disorder Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Generalized Anxiety Disorder Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Generalized Anxiety Disorder NDA approvals (if any), and product development activities comprising the technology, Generalized Anxiety Disorder collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

To explore more information on the latest breakthroughs in the Generalized Anxiety Disorder Pipeline treatment landscape of the report, click here @ Generalized Anxiety Disorder Pipeline Outlook- https://www.delveinsight.com/report-store/generalized-anxiety-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Generalized Anxiety Disorder Pipeline Report
• DelveInsight's Generalized Anxiety Disorder Pipeline analysis depicts a robust space with 10+ active players working to develop 12+ pipeline treatment therapies.
• The leading companies working in the Generalized Anxiety Disorder market include Tilray, Mind Medicine Inc., PSY Therapeutics, Pear Therapeutics, Engrail Therapeutics, Bionomics, Sage Therapeutics, Seed Health, OWP Pharmaceuticals, and others.
• Promising Generalized Anxiety Disorder Pipeline Therapies in the various stages of development include Vortioxetine, Duloxetine, SEP-363856, Troriluzole, Vilazodone, ABBV-932, and others.
• May 2024:- Biohaven Pharmaceuticals- A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Troriluzole in Generalized Anxiety Disorder. The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.
• April 2024:- Big Health Inc.- This study aims to examine the effectiveness of app-based digital CBT for anxiety compared to psychoeducation in individuals with a diagnosis of Generalized Anxiety Disorder. The primary outcomes are anxiety symptom reduction and remission after 10 weeks. This study will examine the effectiveness of digital CBT versus psychoeducation in improving anxiety for those with Generalized Anxiety Disorder.

Generalized Anxiety Disorder Overview
Generalized Anxiety Disorder (GAD) is characterized by persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues.

For further information, refer to the detailed Generalized Anxiety Disorder Unmet Needs, click here for Generalized Anxiety Disorder Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Generalized Anxiety Disorder Emerging Drugs Profile
• MM-120: Mind Medicine, Inc.
• ENX-102: Engrail therapeutics

Generalized Anxiety Disorder Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Generalized Anxiety Disorder. The companies which have their Generalized Anxiety Disorder drug candidates in the mid to advanced stage, i.e. Phase II include, Mind Medicine, Inc.

Request a sample and discover the recent advances in Generalized Anxiety Disorder Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Generalized Anxiety Disorder Segmentation- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Generalized Anxiety Disorder Drugs and Companies
• Vortioxetine: Takeda
• Duloxetine: H. Lundbeck A/S
• SEP-363856: Sumitomo Pharma America Inc.

Generalized Anxiety Disorder Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Generalized Anxiety Disorder Therapeutics Market include-
Tilray, Mind Medicine Inc., PSY Therapeutics, Pear Therapeutics, Engrail Therapeutics, Bionomics, Sage Therapeutics, Seed Health, OWP Pharmaceuticals, and others.

Dive deep into rich insights for drugs for the Generalized Anxiety Disorder Pipeline, Click here @ Generalized Anxiety Disorder Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Generalized Anxiety Disorder Pipeline Report
• Coverage- Global
• Companies- Tilray, Mind Medicine Inc., PSY Therapeutics, Pear Therapeutics, Engrail Therapeutics, Bionomics, Sage Therapeutics, Seed Health, OWP Pharmaceuticals, and others.
• Therapies- Vortioxetine, Duloxetine, SEP-363856, Troriluzole, Vilazodone, ABBV-932, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Generalized Anxiety Disorder Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Generalized Anxiety Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Generalized Anxiety Disorder - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MM-120: Mind Medicine, Inc.
12. Drug profiles in the detailed report…..
13. Preclinical Stage Products
14. PSY-05: PSY Therapeutics
15. Drug profiles in the detailed report…..
16. Discovery Stage Products
17. Pear-011: Pear Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Generalized Anxiety Disorder - Collaborations Assessment- Licensing / Partnering / Funding
21. Generalized Anxiety Disorder - Unmet Needs
22. Generalized Anxiety Disorder - Market Drivers and Barriers
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.